Coronavirus India Live Updates: Supply of Covaxin to Centre at Rs 150 not sustainable in long run, says Bharat Biotech

HORNBILLTV
June 15,2021 03:53 PM
HORNBILL TV

Highlights

Coronavirus (Covid-19) Cases and Lockdown in India Live News Updates: Bharat Biotech said that it has so far invested over Rs 500 crores at risk from its own resources for product development.

Coronavirus India Live Updates: Bharat Biotech Tuesday said that the supply price of its Covid-19 vaccine Covaxin to the central government at Rs 150 per dose is not sustainable in the long run. “Hence a higher price in private markets is required to offset part of the costs,” it said in a statement.

Bharat Biotech said that it has so far invested over Rs 500 crores at risk from its own resources for product development, clinical trials and setting up of manufacturing facilities for Covaxin, it added.

India on Tuesday reported 60,471 new Covid-19 cases, the lowest in 75 days, and 2,726 deaths in the last 24 hours, according to data from the Union Health Ministry. The total number of coronavirus cases in the country now stand at 2,95,70,881 while the death toll has reached 3,77,031. There are 9,13,378 active cases at present while 2,82,80,472 people have recovered so far. As many as 25,90,44,072 people have been vaccinated, the health ministry said.